Dr. Barbara Burtness is a physician-scientist of the Fox Chase Cancer Center and an expert in the treatment of head and neck cancer. At the 2012 American Society of Clinical Oncology Annual Meeting held in Chicago from June 1–5, Dr. Burtness presented an ongoing clinical trial entitled “LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.” Although no results were reported for this Phase 3 trial, Dr. Burtness discussed the results of other studies in head and neck cancer that were presented at ASCO 2012.
